CARY, N.C.--(BUSINESS WIRE)--Biologics, an integrated oncology services company, is proud to announce it has been selected as a specialty pharmacy provider for IMBRUVICA™ (ibrutinib) capsules, now approved by the U.S. Food and Drug Administration (FDA) as a single agent for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Help employers find you! Check out all the jobs and post your resume.
